pERC

pan-Canadian Pharmaceutical Alliance (pCPA): December 2021 Trends and Insights   UPDATE & REQUEST FOR PARTICIPATION IN A SURVEY MORSE has been providing data analytics and expert insights through our pCPA updates on a monthly basis since 2017. Starting in 2022, MORSE will be publishing the pCPA updates quarterly instead of monthly. By analyzing quarterly vs. monthly data we expect to be able to identify important trends and provide useful insights…

pan-Canadian Pharmaceutical Alliance (pCPA): November 2021 Trends and Insights   November 2021 Highlights: 3 products completed CADTH review 15 products initiated pCPA negotiations 3 negotiations were completed with an LOI 0 negotiations were closed without an LOI 1 file was closed without negotiation   Key Take-Aways: The number of files under consideration was reduced substantially from 31 in October to 22 as of November 30th, driven by relatively few CADTH…

pan-Canadian Pharmaceutical Alliance (pCPA): October 2021 Trends and Insights   October 2021 Highlights: 3 products completed CADTH review 6 products initiated pCPA negotiations 8 negotiations were completed with an LOI 0 negotiation were closed without an LOI 0 file were closed without negotiation   Key Take-Aways: The volume of files under consideration has decreased steadily over the past three months from 37 in August to 31 as of October 31st.…

pan-Canadian Pharmaceutical Alliance (pCPA): September 2021 Trends and Insights   September 2021 Highlights: 5 products completed CADTH review 7 products initiated pCPA negotiations 7 negotiations were completed with an LOI 1 negotiation was closed without an LOI 1 file was closed without negotiation   Key Take-Aways: The number of files under consideration at pCPA decreased slightly to 34 from last month’s high, while the average days under consideration had a…

pan-Canadian Pharmaceutical Alliance (pCPA): August 2021 Trends and Insights   August 2021 Highlights: 8 products completed CADTH review 4 products initiated pCPA negotiations 10 negotiations were completed with an LOI No negotiations were closed without an LOI No files were closed without negotiation   Key Take-Aways: The output of the pCPA in August was a high number of completed negotiations and slightly less files initiated for negotiations than usual. Partly…

pan-Canadian Pharmaceutical Alliance (pCPA): July 2021 Trends and Insights   July 2021 Highlights: 5 products completed CADTH review 5 products initiated pCPA negotiations 3 negotiations were completed with an LOI 1 negotiation was closed without an LOI 1 file was closed without negotiation   Key Take-Aways: CADTH released no non-oncology recommendations in July. The volume of files under consideration remains relatively stable in July at 30, with no decrease in…

pan-Canadian Pharmaceutical Alliance (pCPA): June 2021 Trends and Insights   June 2021 Highlights: 8 products completed CADTH review 12 products initiated pCPA negotiations 3 negotiations were completed with an LOI 0 negotiations were closed without an LOI 2 files were closed without negotiation   Key Take-Aways: The volume of files under consideration remains stable with a slight decrease in the days under consideration in June relative to the last 6…

pan-Canadian Pharmaceutical Alliance (pCPA): May 2021 Trends and Insights   May 2021 Highlights: 6 products completed CADTH review 3 products initiated pCPA negotiations 3 negotiations were completed with an LOI 1 negotiation was closed without an LOI 0 files were closed without negotiation   Key Take-Aways: May sees continued consistency in both the volume of files under consideration and the average days under consideration which is hovering around the 5-month…

pan-Canadian Pharmaceutical Alliance (pCPA): April 2021 Trends and Insights   April 2021 Highlights: 5 products completed CADTH review 6 products initiated pCPA negotiations 4 negotiations were completed with an LOI 1 negotiation was closed without an LOI 0 file was closed without negotiation   Key Take-Aways: The volume of files under consideration has remained relatively high and stable for the last 5 months (27-30), although the ratio of oncology to…

pan-Canadian Pharmaceutical Alliance (pCPA): March 2021 Trends and Insights   March 2021 Highlights: 5 products completed CADTH review 3 products initiated pCPA negotiations 2 negotiations were completed with an LOI 3 negotiations were closed without an LOI 0 files were closed without negotiation   Key Take-Aways: The average duration that files are under consideration reaches an annual peak of ~160 days. In addition, the number of files under consideration matches…

pan-Canadian Pharmaceutical Alliance (pCPA): February 2021 Trends and Insights   February 2021 Highlights: 5 products completed CADTH review 7 products initiated pCPA negotiations 6 negotiations were completed with an LOI 0 negotiations were closed without an LOI 1 file was closed without negotiation   Files Under pCPA Consideration: CADTH issued 5 new recommendations in February (28 files under pCPA consideration as of Feb 28) – down from 29 in January.…

pan-Canadian Pharmaceutical Alliance (pCPA): January 2021 Trends and Insights   January 2021 Highlights: 4 products completed CADTH review 9 products initiated pCPA negotiations 5 negotiations were completed with an LOI 0 negotiations were closed without an LOI 1 file was closed without negotiation Files Under pCPA Consideration: CADTH issued 4 new recommendations & notifications to implement in January (29 files under pCPA consideration as of January 31) – down from…

pan-Canadian Pharmaceutical Alliance (pCPA): December 2020 Trends and Insights   December 2020 Highlights: 8 products completed CADTH review 2 products initiated pCPA negotiations 4 negotiations were completed with an LOI 1 negotiation was closed without an LOI 0 files were closed without negotiation Beginning this month and over the next few months, the pCPA is introducing a Targeted Negotiation Process (TNP) to address selected files that have been on hold…

pan-Canadian Pharmaceutical Alliance (pCPA): November 2020 Trends and Insights   November 2020 Highlights: 4 products completed CADTH review 8 products initiated pCPA negotiation 5 negotiations were completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation   Files Under pCPA Consideration: CADTH issued 4 new recommendations & notifications to implement in November (24 files under pCPA consideration as of November 30) – down…

pan-Canadian Pharmaceutical Alliance (pCPA): October 2020 Trends and Insights   October 2020 Highlights: 5 products completed CADTH review 7 products initiated pCPA negotiations 5 negotiations were completed with an LOI 0 negotiations were closed without an LOI 2 files were closed without negotiation   Files Under pCPA Consideration: CADTH issued 5 new recommendations in October (22 files as of October 31). PRODUCT INDICATION SPONSOR Type REC’N* DATE Xtandi** (enzalutamide) Metastatic…